NeuroMetrix Inc (NURO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NeuroMetrix Inc (NURO) has a cash flow conversion efficiency ratio of -0.132x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.89 Million) by net assets ($14.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of NeuroMetrix Inc to measure how much of total assets are equity-financed.
NeuroMetrix Inc - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how NeuroMetrix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is NeuroMetrix Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
NeuroMetrix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NeuroMetrix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HK Metals Utama Tbk PT
JK:HKMU
|
0.222x |
|
Pharmena S.A.
WAR:PHR
|
-0.078x |
|
Fortune Rise Acquisition Corp
NASDAQ:FRLA
|
-0.009x |
|
Pilot Energy Ltd
AU:PGY
|
-0.287x |
|
Nuchev Ltd
AU:NUC
|
-0.107x |
|
CMO Public Company Limited
BK:CMO
|
0.171x |
|
Cabnet Holdings Bhd
KLSE:0191
|
0.009x |
|
Check Cap Ltd
NASDAQ:CHEK
|
0.000x |
Annual Cash Flow Conversion Efficiency for NeuroMetrix Inc (2002–2024)
The table below shows the annual cash flow conversion efficiency of NeuroMetrix Inc from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see market value of NeuroMetrix Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.31 Million | $-7.13 Million | -0.498x | -64.46% |
| 2023-12-31 | $20.09 Million | $-6.08 Million | -0.303x | -33.73% |
| 2022-12-31 | $23.36 Million | $-5.29 Million | -0.226x | -153.54% |
| 2021-12-31 | $23.22 Million | $-2.07 Million | -0.089x | +77.32% |
| 2020-12-31 | $5.25 Million | $-2.07 Million | -0.394x | +72.48% |
| 2019-12-31 | $2.53 Million | $-3.62 Million | -1.431x | -404.96% |
| 2018-12-31 | $6.10 Million | $2.86 Million | 0.469x | +118.61% |
| 2017-12-31 | $5.02 Million | $-12.65 Million | -2.522x | +17.05% |
| 2016-12-31 | $4.96 Million | $-15.08 Million | -3.040x | -191.53% |
| 2015-12-31 | $12.56 Million | $-13.10 Million | -1.043x | +54.00% |
| 2014-12-31 | $3.39 Million | $-7.68 Million | -2.267x | -148.83% |
| 2013-12-31 | $7.19 Million | $-6.55 Million | -0.911x | +12.62% |
| 2012-12-31 | $8.80 Million | $-9.18 Million | -1.043x | -70.56% |
| 2011-12-31 | $11.09 Million | $-6.78 Million | -0.611x | +7.21% |
| 2010-12-31 | $20.20 Million | $-13.31 Million | -0.659x | -283.34% |
| 2009-12-31 | $35.71 Million | $-6.14 Million | -0.172x | +63.29% |
| 2008-12-31 | $22.83 Million | $-10.69 Million | -0.468x | -173.81% |
| 2007-12-31 | $46.73 Million | $-7.99 Million | -0.171x | -201.69% |
| 2006-12-31 | $43.41 Million | $7.30 Million | 0.168x | +219.38% |
| 2005-12-31 | $36.25 Million | $1.91 Million | 0.053x | +167.61% |
| 2004-12-31 | $34.06 Million | $-2.65 Million | -0.078x | -191.47% |
| 2003-12-31 | $-45.50 Million | $-3.87 Million | 0.085x | -25.46% |
| 2002-12-31 | $-39.93 Million | $-4.56 Million | 0.114x | -- |
About NeuroMetrix Inc
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endoc… Read more